CGON · Cg Oncology Inc
United States · RS rating 54 · As of 2026-11-03
| Price | 64.06 USD |
|---|---|
| 1-day change | +3.4% |
| RS rating (overall / 1M / 3M / 12M) | 54 / 41 / 43 / 84 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 41 / 47 / 10 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -26.8% |
| Sales growth Q/Q | +39.4% |
| Distance from 52-week high | +20.6% |
| Market cap (USD) | $5.9B |